CCC Intelligent Solutions appoints new president
CCC Intelligent Solutions (CCC) has named Tim Welsh as its new president, effective from 24 March.
Welsh will head all market-facing functions to support CCC's clients in their digital transformation.
He recently led a digital overhaul at US Bank within the $10bn consumer and small-business banking division.
His background includes more than 26 years at McKinsey & Company, where he provided operational guidance to property and casualty (P&C) and life insurers.
During his tenure at McKinsey, he served as senior partner and was elected to the company's shareholders council, akin to the board of directors.
He also took charge of McKinsey's global learning and development initiatives.
CCC chairman and CEO Githesh Ramamurthy said: 'Tim's extensive expertise across the insurance economy and in digital transformation will help our customers accelerate their journeys with confidence. He comes with a deep working knowledge of the broader industry that will enable him to make an immediate impact on our repair, insurance and auto manufacturing customers.'
Welsh added: 'I am very excited to join CCC and help customers accelerate their digital evolution. CCC's industry-leading AI, expansive network and CCC IX Cloud™ platform are foundational to these efforts. The team is unmatched in their understanding of how customers from independent repair facilities to the largest carriers can leverage these tools to meet their needs.'
Last month, the company concluded a $730m deal to acquire EvolutionIQ, which specialises in managing disability and injury claims.
CCC disbursed 60% of the purchase price in cash, while the remaining 40% was settled in CCC Intelligent Solutions Holdings common stock.
"CCC Intelligent Solutions appoints new president " was originally created and published by Life Insurance International, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Galatea Bio and Fabric Genomics Partner to Deliver Comprehensive Genetic Testing for Common Diseases
MIAMI & OAKLAND, Calif.--(BUSINESS WIRE)-- Galatea Bio and Fabric Genomics, a GeneDx company, announced today a strategic collaboration to enhance genetic testing by incorporating both rare pathogenic variant analysis and polygenic risk scoring (PRS) to assess genetic susceptibility to common diseases. 'By leveraging Fabric Genomics' high-quality clinical gene panel interpretation to support Galatea's polygenic risk score reporting, we are enabling more personalized assessments of an individual's risk for common diseases,' said Martin Reese. The initial offering will include an inherited cardiovascular gene panel based on American Heart Association (AHA) recommendations, with additional PRS for cardiovascular related traits, including coronary arterial disease, high low-density lipoprotein (LDL), elevated triglycerides, low high-density lipoprotein (HDL), atrial fibrillation, hypertension, type 2 diabetes and hypothyroidism. A follow-up offering will integrate hereditary cancer panels with PRS for breast, colorectal, and prostate cancers. 'Galatea Bio is committed to making common genetic risk prediction more accurate for all,' said Carlos Bustamante, Ph.D., CEO & Co-Founder, Galatea Bio. 'Through our collaboration with Fabric Genomics, we're working to capture both rare and common genetic contributions to disease risk—delivering meaningful insights to individuals across the US and around the world.' This collaboration integrates Fabric Genomics' platform for clinical reporting and its expertise in clinical gene panel curation with Galatea Bio's advanced PRS algorithms. By combining these capabilities, the partnership provides both rare variant and polygenic genetic risk reporting using the Broad Clinical Lab's (BCL) Blended Genome - Exome. A key component of this collaboration is the integration of Galatea Bio's newly released individually-adjusted PRS solution, StrataRisk™ PRS, which provides genetic risk for individuals of all ancestries. This is made possible through a novel, proprietary algorithm that leverages data from the Galatea Bio Global Biobank to calibrate PRS scores against similar individuals in genomic ancestry space, ensuring equitable risk assessment across diverse populations. 'By leveraging Fabric Genomics' high-quality clinical gene panel interpretation to support Galatea's polygenic risk score reporting, we are enabling more personalized assessments of an individual's risk for common diseases,' said Martin Reese, Ph.D., President of Fabric Genomics. 'This combined approach allows us to better explain patients' results with a more accurate risk profile.' Evaluating both rare genetic disease variants and polygenic risk scores can have several advantages over reporting either of these independently. Traditional single-gene or multi-gene panel testing focuses on high-penetrance rare mutations, which capture a subset of patients with an inherited single gene disease and often results in negative or uncertain results, leaving many patients' risk unexplained. PRS, which aggregates the cumulative effect of numerous common genetic variants, can provide refined risk stratification. 'This collaboration between Fabric Genomics and Galatea Bio is enabled by our clinical Blended Genome - Exome,' said Niall Lennon, Ph.D., Chief Scientific Officer, Broad Clinical Labs. 'This is exactly the kind of application we envisioned for this cost-effective approach—one that will provide a more comprehensive view of genetic susceptibility to important common diseases.' About Fabric Genomics Fabric Genomics, a GeneDx company, is democratizing genomics-driven precision medicine. The company provides institutions with end-to-end clinical sequencing solutions that include the Fabric Enterprise software platform, assay design and validation support and the clinical interpretation services needed to scale genetic testing. At the core of this platform is a suite of sophisticated AI algorithms and data knowledge systems that turn data into expert clinical insights. Headquartered in Oakland, California, Fabric Genomics supports clinical applications across a variety of use cases including rare disease, oncology, cardiovascular, neurological and women's health. To learn more, visit and follow us on X and LinkedIn. About GeneDx At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world's largest, rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery and improve health system efficiencies. For more information, please visit and connect with us on LinkedIn, Facebook and Instagram. About Galatea Bio Galatea Bio is an innovative, venture-backed biotechnology company that strives to advance 'Precision Health at Scale for All.' Founded by pioneers in the fields of population genetics and bioinformatics, Galatea Bio leverages cutting-edge ancestry algorithms to scale the promise of precision health to global populations, while maintaining a strong commitment to ethical research. The company is headquartered in Miami Lakes, Florida. For more information, visit or follow us on X and LinkedIn. About the Broad Clinical Labs Broad Clinical Laboratories was founded in 2013 as a non-profit subsidiary of Broad Institute of MIT and Harvard to accelerate the world toward a better understanding, diagnosis and treatment of disease by pursuing projects, developing products and driving adoption of cutting edge genomics technologies and novel molecular assays. Broad Clinical Labs is a leader in translational genomics, having sequenced over 700,000 genomes in service of its mission to accelerate the understanding and diagnosis of human disease. Forward Looking Statements This press release may contain 'forward-looking statements' within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words 'believe,' 'project,' 'expect,' 'anticipate,' 'estimate,' 'intend,' 'strategy,' 'future,' 'opportunity,' 'plan,' 'may,' 'should,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result,' and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business combinations, plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, (iv) our ability to pursue our new strategic direction, and (v) our ability to enhance our artificial intelligence tools that we use in our clinical interpretation platform. The foregoing list of factors is not exhaustive. A further list and description of risks, uncertainties and other matters can be found in the 'Risk Factors' section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.
Business Wire
3 hours ago
- Business Wire
University of Phoenix and Jobs for the Future Partner to Help Employers Harness Effective Upskilling and Reskilling at Scale
PHOENIX--(BUSINESS WIRE)-- University of Phoenix and Jobs for the Future (JFF), a national nonprofit driving transformation in the U.S. workforce and education systems, announce a new project in their continued partnership; to pilot and evaluate an AI-powered skills analysis and upskilling business outcomes strategy that accurately captures and understands employee skills, tech integration and employer adoption of skills pathways for their workforce. The collaboration comes at a pivotal moment. According to the World Economic Forum, 39% of core job skills are expected to change by 2030. Yet many organizations still do not center understanding of workforce skills and development opportunities in their business strategy; the 2025 Career Optimism Index® study found that while 86% of workers are actively seeking skill development opportunities, employer investment in reskilling and upskilling has declined by 13 and 10 points, respectively, since 2022. 'As AI reshapes the workforce, the companies that thrive won't necessarily be those with the best technology, but those with the most adaptable people,' said Raghu Krishnaiah, Chief Operating Officer at University of Phoenix. 'We seek to close the gap between aspiration and action by effective implementation of a business strategy that centers the skills needed for the success of the organization and embeds learning and career pathways for employees based on their skillsets.' The project aims to uncover how skills-focused, AI-enabled tools can drive better outcomes in employee development, retention, and mobility—while also addressing critical issues like algorithmic transparency and data accountability. With support from University of Phoenix, JFF will conduct discovery and analysis, including exploration of strategies that create impact through skills validation and upskilling; and then through piloting, testing and market experience with employers that feature diversely skilled workforce populations. The initiative will conduct analysis and testing with the University's technology affiliate, Skillmore™, an AI skills intelligence platform, in collaboration with employers. 'During this critical adoption phase of AI technology platforms by companies, JFF is deeply committed to a thorough examination of these platforms to better understand employer and employee impact, as well as to support responsible AI design,' states Alison Lands, Vice President, Employer & Workforce Solutions, JFF. 'This initiative allows us to co-design solutions that are innovative and responsive to the needs of a broad and evolving workforce.' The shared project highlights mission alignment between the two organizations in supporting working adult learners: JFF has established a North Star that by 2033, 75 million people facing barriers to economic advancement will have quality jobs, and the mission of University of Phoenix is to provide access to higher education opportunities that enable students to develop the knowledge and skills necessary to achieve their professional goals, improve the performance of their organizations and provide leadership and service to their communities. 'Our work with JFF is about turning good intentions around learning and development into real, measurable progress, allowing us to build greater confidence in AI-generated recommendations and make transparent technology's role in promoting talent mobility,' shares Krishnaiah. 'Together, we can help employers unlock vital support services for creating holistic talent solutions and career pathways for the learners and workers we aim to serve.' The partnership highlights the University's collaboration with 2,000+ employers through its Adaptable Skills Solutions, offering customized workforce assessments in partnership with the University's technology affiliate Skillmore TM for a transformational combination with professional development and discounted education benefits. Skillmore TM is a trademark of Talent Mobility, Inc. Talent Mobility, Inc. (dba Skillmore) is an affiliate of University of Phoenix and requires a separate agreement for its services. The project will run through May 2026 and culminate in a field-facing impact report offering actionable insights for employers, educators, and technology developers. About University of Phoenix University of Phoenix innovates to help working adults enhance their careers and develop skills in a rapidly changing world. Flexible schedules, relevant courses, interactive learning, skills-mapped curriculum for our bachelor's and master's degree programs and a Career Services for Life® commitment help students more effectively pursue career and personal aspirations while balancing their busy lives. . JFF is building a future that works for everyone by transforming U.S. education and workforce systems to drive economic success for people, businesses, and communities. Learn more at
Business Upturn
4 hours ago
- Business Upturn
Live Biotherapeutics at a Crossroad: Novotech White Paper Outlines Opportunities and Early-Stage Challenges
Sydney, Australia: As Live Biotherapeutic Products (LBPs) begin to transition from frontier science to clinical reality, Novotech, a leading global CRO and scientific advisory partner has published a new white paper examining the opportunities and challenges shaping this fast-evolving landscape of therapeutic class. This press release features multimedia. View the full release here: LBPs, which harness live microorganisms to restore or modulate human health, are being explored across a growing range of indications, from gastrointestinal and metabolic disorders to CNS and oncology. FDA approvals of Rebyota™ and Vowst™ have validated the category but for most biotech sponsors, the journey remains uncertain. According to Novotech's analysis, over 90% of LBP assets are still in early development stages, and nearly one-third of all trials from 2020 to 2025 have been withdrawn or suspended due to regulatory, manufacturing, or design complexities. Highlights from the report include: A growing pipeline of preclinical and Phase I–II LBP candidates, with notable concentration in Alzheimer's, IBD, diabetes, and NASH. Over 90 industry-sponsored trials launched since 2020, yet 32% have experienced discontinuation. North America and Europe leading in regulatory approvals and manufacturing activity, with rising interest from biotechs in Asia-Pacific. A projected CAGR of 38% for the LBP and microbiome CDMO market through 2030. The global market for LBPs and microbiome contract development and manufacturing organizations (CDMOs) was valued at USD 31.84 million in 2023. With growing investment in players like Vedanta Biosciences and MaaT Pharma, the LBP field is maturing but also becoming more competitive. Success will depend on smart trial design, global regulatory navigation, and efficient feasibility execution. Drawing on deep therapeutic expertise in microbiome-related studies and gastrointestinal, metabolic, and immunologic indications, Novotech supports sponsors from early development through global trial delivery. With operations spanning Asia-Pacific, North America, and Europe, Novotech is uniquely positioned to help biotech and small to mid-size pharma companies translate LBP potential into clinical success. Download the full white paper 'Why Live Biotherapeutics Matter to Emerging Biotech' here. For further information, please visit About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results. For more information or to speak to an expert team member visit View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
